Sarcopenia and Parkinson's disease: molecular mechanisms and clinical management

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F19%3A00072538" target="_blank" >RIV/00159816:_____/19:00072538 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Sarcopenia and Parkinson's disease: molecular mechanisms and clinical management

Popis výsledku v původním jazyce

Parkinson&apos;s disease (PD) is a degenerative disorder of the central nervous system that affects the motor system. In the early stages of the disease, major symptoms include shaking, rigidity, slowness of movement, and diffculty with walking and gait (Kalia and Lang 2015). Late appearing symptoms include thinking and behavioral problems, with dementia occurring very often in the advanced stages of PD, and depression as the most common psychiatric co-morbidity. Additional symptoms include also sensory and sleep issues. The main motor symptoms are collectively called parkinsonism (Kalia and Lang 2015). Worldwide PD affects ~50 million people with ~100,000 deaths each year. The life expectancy of people with PD is signifcantly reduced, with mortality ratios around twice or more those of people without PD. Mortality risk factors include cognitive decline and dementia, old age at onset, and presence of swallowing impairments. Death from aspiration pneumonia occurs twice as often in individuals with PD as in the healthy population. Sarcopenia is the degenerative loss of skeletal muscle tissue mass, integrity, and strength associated with increasing age. Sarcopenia is part of the frailty syndrome and often part of cachexia, but it can also exist independently of cachexia. Sarcopenia is a risk factor for falls and consequent fractures in old people with PD. Most adults affected by PD display signifcantly compromised bone and muscle health. The aim of this review is to summarize the state-of-the-art knowledge about sarcopenia in PD in terms of causes, mechanisms of onset, and therapeutic management.

Název v anglickém jazyce

Sarcopenia and Parkinson's disease: molecular mechanisms and clinical management

Popis výsledku anglicky

Parkinson&apos;s disease (PD) is a degenerative disorder of the central nervous system that affects the motor system. In the early stages of the disease, major symptoms include shaking, rigidity, slowness of movement, and diffculty with walking and gait (Kalia and Lang 2015). Late appearing symptoms include thinking and behavioral problems, with dementia occurring very often in the advanced stages of PD, and depression as the most common psychiatric co-morbidity. Additional symptoms include also sensory and sleep issues. The main motor symptoms are collectively called parkinsonism (Kalia and Lang 2015). Worldwide PD affects ~50 million people with ~100,000 deaths each year. The life expectancy of people with PD is signifcantly reduced, with mortality ratios around twice or more those of people without PD. Mortality risk factors include cognitive decline and dementia, old age at onset, and presence of swallowing impairments. Death from aspiration pneumonia occurs twice as often in individuals with PD as in the healthy population. Sarcopenia is the degenerative loss of skeletal muscle tissue mass, integrity, and strength associated with increasing age. Sarcopenia is part of the frailty syndrome and often part of cachexia, but it can also exist independently of cachexia. Sarcopenia is a risk factor for falls and consequent fractures in old people with PD. Most adults affected by PD display signifcantly compromised bone and muscle health. The aim of this review is to summarize the state-of-the-art knowledge about sarcopenia in PD in terms of causes, mechanisms of onset, and therapeutic management.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

<a href="/cs/project/EF15_003%2F0000492" target="_blank" >EF15_003/0000492: Mapování molekulární podstaty procesů stárnutí pro vývoj nových léčebných metod</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Sarcopenia: Molecular, Cellular, and Nutritional Aspects – Applications to Humans

ISBN

978-1-4987-6513-8

Počet stran výsledku

25

Strana od-do

1-25

Počet stran knihy

432

Název nakladatele

CRC Press

Místo vydání

USA

Kód UT WoS kapitoly

—